{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:26:58Z","timestamp":1786638418821,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"by the project of Zhenjiang Key Laboratory of Health and Life Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00891-6","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:25:27Z","timestamp":1786634727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Active ingredients and molecular targets of Tripterygium wilfordii against colorectal cancer: network pharmacology, molecular docking, molecular dynamics simulations and in vitro evaluation"],"prefix":"10.1007","volume":"40","author":[{"given":"Qian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongxun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"2","key":"891_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2012","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet\u2010Tieulent J, Jemal A (2012) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87\u2013108","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"891_CR2","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"891_CR3","first-page":"115","volume":"66","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2015) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115\u2013132","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"891_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/BF02954997","volume":"27","author":"S Liu","year":"2015","unstructured":"Liu S, Zheng R, Zhang M, Zhang S, Sun X, Chen W (2015) Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res 27(1):22","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"891_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"D Longley","year":"2005","unstructured":"Longley D, Johnston P (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275\u2013292","journal-title":"J Pathol"},{"issue":"12","key":"891_CR6","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.3390\/cancers14122928","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Shen X, Chen G, Du J (2022) Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 14(12):2928","journal-title":"Cancers"},{"issue":"2","key":"891_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.soc.2021.11.006","volume":"31","author":"S Sakata","year":"2022","unstructured":"Sakata S, Larson DW (2022) Targeted therapy for colorectal cancer. Surg Oncol Clin N Am 31(2):255\u2013264","journal-title":"Surg Oncol Clin N Am"},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02130-2","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Ji Q, Li Q (2021) Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 40:1\u201317","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"891_CR9","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4(1):47\u201353","journal-title":"J Natl Cancer Cent"},{"key":"891_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109624","volume":"121","author":"R Li","year":"2020","unstructured":"Li R, Li Q, Ji Q (2020) Molecular targeted study in tumors: from western medicine to active ingredients of traditional Chinese medicine. Biomed Pharmacother 121:109624","journal-title":"Biomed Pharmacother"},{"key":"891_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7770380","author":"L Peng","year":"2022","unstructured":"Peng L, Zhang K, Li Y, Chen L, Gao H, Chen H (2022) Real\u2010world evidence of traditional Chinese medicine (TCM) treatment on cancer: a literature\u2010based review. Evid Based Complement Alternat Med. https:\/\/doi.org\/10.1155\/2022\/7770380","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"891_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/br.2015.537","volume":"4","author":"J Nie","year":"2016","unstructured":"Nie J, Zhao C, Deng L, Chen J, Yu B, Wu X, Pang P, Chen X (2016) Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep 4(1):3\u201314","journal-title":"Biomed Rep"},{"issue":"1","key":"891_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jep.2014.06.006","volume":"155","author":"X-J Li","year":"2014","unstructured":"Li X-J, Jiang Z-Z, Zhang L-y (2014) Triptolide: progress on research in pharmacodynamics and toxicology. J Ethnopharmacol 155(1):67\u201379","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"891_CR14","first-page":"622","volume":"26","author":"C Meng","year":"2014","unstructured":"Meng C, Zhu H, Song H, Wang Z, Huang G, Li D, Ma Z, Ma J, Qin Q, Sun X (2014) Targets and molecular mechanisms of triptolide in cancer therapy. Chin J Cancer Res 26(5):622","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"891_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1389200219666180816141506","volume":"20","author":"W Song","year":"2019","unstructured":"Song W, Liu M, Wu J, Zhai H, Chen Y, Peng Z (2019) Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab 20(2):147\u2013154","journal-title":"Curr Drug Metab"},{"issue":"5","key":"891_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.tips.2019.03.002","volume":"40","author":"P Noel","year":"2019","unstructured":"Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H (2019) Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci 40(5):327\u2013341","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"891_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11655-018-2847-z","volume":"25","author":"Y-m Wei","year":"2019","unstructured":"Wei Y-m, Wang Y-h, Xue H-q, Luan Z-h, Liu B-w, Ren J-h (2019) Triptolide, a potential autophagy modulator. Chin J Integr Med 25(3):233\u2013240","journal-title":"Chin J Integr Med"},{"issue":"2","key":"891_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jss.2009.07.002","volume":"168","author":"SM Johnson","year":"2011","unstructured":"Johnson SM, Wang X, Evers BM (2011) Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res 168(2):197\u2013205","journal-title":"J Surg Res"},{"issue":"1","key":"891_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s40001-023-01453-4","volume":"28","author":"F Jin","year":"2023","unstructured":"Jin F, Ni X, Yu S, Jiang X, Zhou J, Mao D, Liu Y, Wu F (2023) Network pharmacology-based investigation of potential targets of triptonodiol acting on non-small-cell lung cancer. Eur J Med Res 28(1):547","journal-title":"Eur J Med Res"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-020-02885-9","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang J, Huang Q, Zhao R, Ma Z (2020) A network pharmacology study on the Tripteryguim wilfordii Hook for treatment of Crohn\u2019s disease. BMC Complement Med Ther 20:1\u20138","journal-title":"BMC Complement Med Ther"},{"key":"891_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118888","author":"G-L Zhou","year":"2024","unstructured":"Zhou G-L, Su S-L, Yu L, Shang E-X, Hua Y-Q, Yu H, Duan J-a (2024) Exploring the liver toxicity mechanism of Tripterygium wilfordii extract based on metabolomics, network pharmacological analysis and experimental validation. J Ethnopharmacol. https:\/\/doi.org\/10.1016\/j.jep.2024.118888","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"891_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0300-9084(01)01356-6","volume":"84","author":"D Guimaraes","year":"2002","unstructured":"Guimaraes D, Hainaut P (2002) TP53: a key gene in human cancer. Biochimie 84(1):83\u201393","journal-title":"Biochimie"},{"issue":"9","key":"891_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y (2020) PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11(9):797","journal-title":"Cell Death Dis"},{"issue":"11","key":"891_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798\u2013809","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"891_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15\u201331","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"891_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/bab.2233","volume":"69","author":"M Asadi","year":"2022","unstructured":"Asadi M, Taghizadeh S, Kaviani E, Vakili O, Taheri-Anganeh M, Tahamtan M, Savardashtaki A (2022) Caspase-3: structure, function, and biotechnological aspects. Biotechnol Appl Biochem 69(4):1633\u20131645","journal-title":"Biotechnol Appl Biochem"},{"issue":"6","key":"891_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","volume":"21","author":"J-F Rossi","year":"2015","unstructured":"Rossi J-F, Lu Z-Y, Jourdan M, Klein B (2015) Interleukin-6 as a therapeutic target. Clin Cancer Res 21(6):1248\u20131257","journal-title":"Clin Cancer Res"},{"issue":"6","key":"891_CR28","first-page":"691","volume":"2","author":"JY Zhang","year":"2012","unstructured":"Zhang JY, Selim MA (2012) The role of the c-Jun N-terminal kinase signaling pathway in skin cancer. Am J Cancer Res 2(6):691","journal-title":"Am J Cancer Res"},{"issue":"1","key":"891_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gene.2015.06.018","volume":"570","author":"AD Zuehlke","year":"2015","unstructured":"Zuehlke AD, Beebe K, Neckers L, Prince T (2015) Regulation and function of the human HSP90AA1 gene. Gene 570(1):8\u201316","journal-title":"Gene"},{"key":"891_CR30","doi-asserted-by":"crossref","unstructured":"Wajant H (2009) The role of TNF in cancer. In: Death receptors and cognate ligands in cancer 2009, pp 1\u201315","DOI":"10.1007\/400_2008_26"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13402-020-00534-4","volume":"43","author":"B Chen","year":"2020","unstructured":"Chen B, Li L, Li M, Wang X (2020) HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers. Cell Oncol 43:877\u2013888","journal-title":"Cell Oncol"},{"issue":"11","key":"891_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, Wu S, Wang Y (2023) SRplot: a free online platform for data visualization and graphing. PLoS ONE 18(11):e0294236","journal-title":"PLoS ONE"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00891-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00891-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00891-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:25:29Z","timestamp":1786634729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00891-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00891-6","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial and nonfinancial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"202"}}